Our research on the impact of increased periods of data exclusivity in Japan and Canada on pharmaceutical spending is mentioned in this Washington Post article. Post navigation Previous Article Previous Article New study: More medicines have their price raised by import duties Next Article Next Article Geneva Network statement on UN High Level Panel on Access to Medicines You may also like Why Voluntary Licensing is Best for Increasing Access to Medicines News Reforming Indonesia’s 2016 patent act News